The Centers for Disease Control and Prevention (CDC), specifically the National Center on Birth Defects and Developmental Disabilities (NCBDDD), is forecasting a funding opportunity under the title “Enhancing Public Health Surveillance of Bleeding Disorders” (CDC-RFA-DD-25-0124). This cooperative agreement aims to improve the public health surveillance of inherited bleeding disorders, such as hemophilia and von Willebrand disease, through the collection and utilization of data from federally supported hemophilia treatment centers. The program will support research and data initiatives to inform clinical practices and policy decisions, thereby enhancing health outcomes and reducing the burden on individuals living with these disorders.

The primary objectives of this funding opportunity include developing comprehensive data on bleeding disorders, analyzing current treatment practices, monitoring health complications like inhibitor development, and identifying risk factors associated with mortality in affected populations. This surveillance infrastructure will enhance understanding of bleeding disorders and contribute to improvements in treatment protocols. By focusing on these areas, the program intends to address significant health disparities and improve the quality of life for those with bleeding disorders.

Funding for this cooperative agreement is expected to total $21.5 million, with awards ranging from $100,000 to a maximum of $4.3 million. One award is anticipated, with no cost-sharing or matching funds required from recipients. Eligible applicants include a broad range of entities, such as public and state-controlled institutions of higher education, nonprofits with and without 501(c)(3) status, special district governments, city and county governments, public housing authorities, federally recognized Native American tribal governments, private institutions of higher education, small businesses, and for-profit organizations other than small businesses. This wide eligibility aims to attract applicants capable of managing significant data collection and surveillance activities.

Applications are expected to be submitted electronically by May 15, 2025, no later than 11:59 pm ET. Interested applicants should prepare to address the specific surveillance and data collection needs outlined in the funding announcement, including mechanisms for data collection, analysis, and reporting to support ongoing policy and clinical improvements. CDC will evaluate proposals based on the applicants’ capability to conduct data-driven surveillance and implement strategies that align with program goals.

The estimated post date for the full funding announcement is March 1, 2025. Key dates include an estimated award announcement on August 31, 2025, and a project start date of September 30, 2025. Proposals will be evaluated on their alignment with the CDC's goals of reducing health complications and mortality while improving the quality of life for individuals with bleeding disorders. Evaluation criteria are likely to emphasize applicants’ experience in public health surveillance, data infrastructure capabilities, and strategies for sustainable health improvements.

For further information or questions, applicants may contact Brandi Dupervil at (404) 498-6879 or via email at inm4@cdc.gov.